オメプラゾールによる十二指腸潰瘍の急速な治癒:二重盲検の投与量比較試験
Lancet (London, England)
|July 16, 1983
まとめ
より高いオメプラゾール用量 (60 mg/日) は,より低い用量 (20 mg/日) と比較して,十二指腸潰瘍の治癒率を大幅に改善しました. ほとんどの患者は治ったが,一部の患者は一時的な肝臓酵素上昇を経験し,オメプラゾールに関するさらなる調査が必要となった.
科学分野:
- 胃腸内科 胃腸内科
- 薬理学 薬理学とは
背景:
- 十二指腸潰瘍は,一般的な胃腸疾患です.
- オメプラゾールなどのプロトンポンプ阻害剤は標準的な治療法です.
研究 の 目的:
- 十二指腸潰瘍の治癒に対するオメプラゾールの2つの投与量 (20 mg/日 vs. 60 mg/日) の有効性を比較する.
- 異なるオメプラゾール用量の安全性を評価する.
主な方法:
- ダブルブラインドで投与量を比較した試験で,十二指腸潰瘍を患った32人の患者が参加した.
- 患者は4週間,オメプラゾールの20mg/日または60mg/日に投与された.
主要な成果:
- オメプラゾール60 mg/日群は2週間で100%の潰瘍治癒を達成し,20 mg/日群 (63%) よりも著しく高かった.
- 4週間後,20 mg/日群の患者の93%が回復しました.
- 血清アラニンアミノトランスフェラーゼの過渡的,軽度の上昇は10人の患者で観察され,1人の患者は顕著な上昇のために離脱されました.
結論:
- より高用量オメプラゾール (60 mg/日) は,十二指腸潰瘍の優れた,より迅速な治癒を示しています.
- 観察された肝臓酵素上昇の原因は,より広範な臨床使用前にオメプラゾールの関与を排除するためにさらなる調査を必要とします.
関連する概念動画
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
Peptic Ulcer Disease II: Pathophysiology
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Peptic Ulcer Disease IV: Management
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Peptic Ulcer Disease II: Pathophysiology
Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...


